Literature DB >> 10698357

In vivo effects of chronic treatment with [MET5]-enkephalin on hematological values and natural killer cell activity in athymic mice.

R Zalys1, I S Zagon, R H Bonneau, C M Lang, P J McLaughlin.   

Abstract

The role of endogenous opioids in immunological mechanisms was examined by subjecting athymic (nu/nu) mice to chronic injections of the opioid agonist [Met5]-enkephalin (MET) or continuous opioid receptor blockade with naltrexone (NTX). After 8 days of treatment, neither excess peptide nor deprivation of opioids from receptors had any effect on body weight, spleen index (spleen to body weight ratio), total and differential white blood cell counts, and natural killer (NK) cell activity in peripheral blood or splenic lymphocytes. At 28 days, chronic treatment with MET or NTX had no effect on any of these parameters with the exception of an elevation from controls in NK cell activity in peripheral blood in mice receiving NTX, and subnormal NK cell activity related to splenic lymphocytes in the MET group. These results suggest that chronic exposure to an opioid agonist, or persistent opioid receptor blockade, have little influence on a variety of immunological properties in athymic mice, suggesting that native opioids such as MET do not play a marked role in defense mechanisms in the athymic mouse.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698357     DOI: 10.1016/s0024-3205(99)00655-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Immune-enhancing effects of gamma-irradiated sericin.

Authors:  In-Bong Song; Hye-Ju Han; Jungkee Kwon
Journal:  Food Sci Biotechnol       Date:  2020-02-10       Impact factor: 2.391

2.  Chemical Synthesis of Sulfated Yeast (Saccharomyces cerevisiae) Glucans and Their In Vivo Antioxidant Activity.

Authors:  Hua Zhang; Jing Zhang; Ziluan Fan; Xintao Zhou; Lin Geng; Zhenyu Wang; Joe M Regenstein; Zhiqiang Xia
Journal:  Molecules       Date:  2017-07-28       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.